Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma
TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.
Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.
"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."
Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.
"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."
Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.
About Ripple Therapeutics
Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com
Piper Sandler acted as the exclusive financial advisor to Ripple.
For further information:
Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988
SOURCE: Ripple Therapeutics
View the original press release on accesswire.com
Ripple Therapeutics
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TruMerit Hails Release of WHO's State of the World's Nursing Report15.5.2025 22:30:00 EEST | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / May 15, 2025 / TruMerit™ (formerly CGFNS International) welcomed the release this week of the World Health Organization's State of the World's Nursing Report, which provides the first comprehensive assessment of global nursing since the COVID-19 pandemic.TruMerit The report highlights a critical imperative to strengthen global nursing capacity in the wake of the pandemic and amid economic uncertainty, climate change impacts, and persistent health inequities. It warns that the global health workforce shortage will continue to widen, reaching 11 million by 2030, thereby requiring a fundamental shift in how countries approach healthcare workforce planning and investment. While emphasizing the urgent need to address this challenge, TruMerit President and CEO Dr. Peter Preziosi, who served on the WHO steering committee that helped guide the report's preparation, pointed to opportunities to leverage the power of nursing to resolve inequities and
Global Sports Brand U.S. Polo Assn. Launches Menswear in Argentina15.5.2025 14:00:00 EEST | Press release
WEST PALM BEACH, FLA./BUENOS AIRES, ARGENTINA / ACCESS Newswire / May 15, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its launch in the Argentine market alongside its brand partners Incom S.p.a. and Sur Pacifico S.A. This entry further enhances the multi-billion-dollar brand's global presence and expands U.S. Polo Assn.'s reach into another new and exciting market.U.S. Polo Assn. The global sports brand's presence in Argentina will focus on a territory steeped in history, where the sport of polo is not only widely celebrated but also deeply rooted in the local culture. U.S. Polo Assn. will commence with the launch of the men's collection in June 2025, featuring timeless styles such as polo shirts, woven shirts, t-shirts, trousers, jeans, knitwear, and jackets. "Partnering with Incom S.p.a. and Sur Pacifico S.A. to bring the U.S. Polo Assn. brand to Argentina for the first time-a country with a profound polo legacy and am
Loar Announces Pricing of Secondary Public Offering15.5.2025 04:55:00 EEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 14, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the pricing of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders at $83.41 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 16, 2025, subject to customary closing conditions. The selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the offering. Moelis & Company, Citigroup and RBC Capital Markets are additionally acting as book runners. Blackstone is acting as co-manager. An automatic shelf regis
Maxon Introduces New Real-Time Rendering and Cinematic Previews Solution for Architects14.5.2025 09:10:00 EEST | Press release
Maxon gives first preview of new solution with partner Vectorworks at AIA Conference on Architecture & Design 2025 BAD HOMBURG, GERMANY / ACCESS Newswire / May 14, 2025 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming and more, is further optimizing its cinematic rendering technology for architectural visualization (ArchViz). For decades, Maxon's technology has empowered top artists to achieve the impossible in both the real world and imaginary-from architecture, construction and product design, to mind-bending visual effects, animation and 3D sculpting. Now, that same level of excellence is being engineered specifically for architects and designers-expanding on the power of Maxon's Cinema 4D and Redshift solutions to meet the demands of real-world, real-time architecture design workflows. Seamlessly integrating with major CAD and BIM tools like Vectorworks, this new platform will allow users t
Loar Announces Launch of Secondary Public Offering13.5.2025 23:26:00 EEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom